Skip to main content

World Ovarian Cancer Day 2023

Following cervical and uterine cancer, ovarian cancer (OC) ranks third in gynecologic cancers for frequency but has the highest rate of death. A woman’s risk of getting ovarian cancer during her lifetime is about 1 in 78, with a mortality rate of around 1 in 108. OC often remains non-diagnosed until it spreads throughout the pelvis and abdomen, making treatment difficult.

For World Ovarian Cancer Day 2023, we'd like to highlight some of our most impactful research and review articles on OC in the last few years, which have extensively contributed to the field.

We'd like to congratulate our authors on this achievement, which cements Journal of Ovarian Research as a top destination for OC content.

For all articles on ovarian cancer, please see here.

For more information on WOCD from the World Ovarian Cancer Coalition including how to get involved, please see here.

Comorbidities and inflammation associated with ovarian cancer and its influence on SARS-CoV-2 infection
Sima Chaudhari, Satyajit Dey Pereira, Meshach Asare-Warehene, Ritam Naha, Shama Prasada Kabekkodu, Benjamin K. Tsang & Kapaettu Satyamoorthy 
Review  |   Published: 25 February 2021


COVID-19 and cytokine storm syndrome: can what we know about interleukin-6 in ovarian cancer be applied?
Antonio Macciò, Sara Oppi & Clelia Madeddu 
Review  |   Published: 08 February 2021


Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer
Zhen Yuan, Ying Zhang, Dongyan Cao, Keng Shen, Qingshui Li, Guonan Zhang, Xiaohua Wu, Manhua Cui, Ying Yue, Wenjun Cheng, Li Wang, Pengpeng Qu, Guangshi Tao, Jianqing Hou, Lixin Sun, Yuanguang Meng, Guiling Li, Changzhong Li, Huirong Shi & Yaqing Chen  
Research  |   Published: 11 January 2021


Ovarian endometrioid carcinoma and clear cell carcinoma: A 21-year retrospective study
Ling Zhou, Liqing Yao, Lin Dai, Honglan Zhu, Xue Ye, Shang Wang, Hongyan Cheng, Ruiqiong Ma, Huiping Liu, Heng Cui & Xiaohong Chang   
Research  |   Published: 04 May 2021


Identification of key genes associated with polycystic ovary syndrome (PCOS) and ovarian cancer using an integrated bioinformatics analysis
Juan Zou, Yukun Li, Nianchun Liao, Jue Liu, Qunfeng Zhang, Min Luo, Jiao Xiao, Yanhua Chen, Mengjie Wang, Kexin Chen, Juan Zeng & Zhongcheng Mo 
Research  |   Published: 28 February 2022


Efficacy of PD-1/PD-L1 inhibitors in ovarian cancer: a single-arm meta-analysis
Jue Zhu, Lifeng Yan & Qiming Wang   
Research  |   Published: 28 August 2021


Investigation on factors associated with ovarian cancer: an umbrella review of systematic review and meta-analyses
Kiarash Tanha, Azadeh Mottaghi, Marzieh Nojomi, Marzieh Moradi, Rezvan Rajabzadeh, Samaneh Lotfi & Leila Janani  
Review  |   Published: 11 November 2021


The impact of Pegylated liposomal doxorubicin in recurrent ovarian cancer: an updated meta-analysis of randomized clinical trials
Xin-Ru Li, Yi Zhu, Guo-Nan Zhang, Jian-Ming Huang & Li-Xia Pei 
Research  |   Published: 09 March 2021


Choosing the right timing for interval debulking surgery and perioperative chemotherapy may improve the prognosis of advanced epithelial ovarian cancer: a retrospective study
Dengfeng Wang, Guonan Zhang, Chunrong Peng, Yu Shi & Xunwei Shi 
Research  |   Published: 27 March 2021


The efficacy and safety of niraparib for ovarian cancer: a single-center observational study from China
Jing Ni, Xianzhong Cheng, Qian Zhao, Zhiqin Dai, Xia Xu, Wenwen Guo, Hongyuan Gu, Rui Zhou, Yan Wang & Xiaoxiang Chen   
Research  |   Published: 17 May 2021


Calculating the dose of cisplatin that is actually utilized in hyperthermic intraperitoneal chemotherapy among ovarian cancer patients
Wu-yun Wang, Miao-fang Wu, Dong-bing Wu, Li-juan Wang, Hui Li, Zhong-qiu Lin & Jing Li 
Research  |   Published: 08 January 2021


Challenges and opportunities for ovarian cancer management in the epidemic of Covid-19: lessons learned from Wuhan, China
Zhilan Chen, Chun Zhang, Jiu Yin, Xin Xin, Hemei Li, Yapei Wang, Benjamin K. Tsang & Qinghua Zhang 
Review  |   Published: 08 February 2021


Maintenance therapy for newly diagnosed epithelial ovarian cancer– a review
Shona Nag, Shyam Aggarwal, Amit Rauthan & Narayanankutty Warrier 
Review |   Published: 28 July 2022


Clinical application of PARP inhibitors in ovarian cancer: from molecular mechanisms to the current status
Yongsong Wu, Shilin Xu, Shanshan Cheng, Jiani Yang & Yu Wang 
Review |   Published: 07 January 2023

Exosome-mediated transfer of CD44 from high-metastatic ovarian cancer cells promotes migration and invasion of low-metastatic ovarian cancer cells
Xiameng Shen, Conghui Wang, Huihui Zhu, Yaping Wang, Xinyu Wang, Xiaodong Cheng, Wanzhong Ge & Weiguo Lu 
Research |   Published: 24 February 2021


MiR-200b is upregulated in plasma-derived exosomes and functions as an oncogene by promoting macrophage M2 polarization in ovarian cancer
Jun Xiong, Xiaoju He, Yuanyuan Xu, Wei Zhang & Fen Fu 
Research |   Published: 02 June 2021


Plasma-derived exosomal miR-4732-5p is a promising noninvasive diagnostic biomarker for epithelial ovarian cancer
Jingjing Liu, Jigeun Yoo, Jung Yoon Ho, Yuyeon Jung, Sanha Lee, Soo Young Hur & Youn Jin Choi 
Research |   Published: 28 April 2021


Integrated clinical characteristics and omics analysis identifies a ferroptosis and iron-metabolism-related lncRNA signature for predicting prognosis and therapeutic responses in ovarian cancer
Songwei Feng, Han Yin, Ke Zhang, Mei Shan, Xuan Ji, Shanhui Luo & Yang Shen 
Research |   Published: 20 January 2022


Curcumin inhibits ovarian cancer progression by regulating circ-PLEKHM3/miR-320a/SMG1 axis
Sifan Sun & Hailiang Fang 
Research |   Published: 16 November 2021


Choosing the right timing for interval debulking surgery and perioperative chemotherapy may improve the prognosis of advanced epithelial ovarian cancer: a retrospective study
Dengfeng Wang, Guonan Zhang, Chunrong Peng, Yu Shi & Xunwei Shi 
Research |   Published: 27 March 2021


COVID-19 and cytokine storm syndrome: can what we know about interleukin-6 in ovarian cancer be applied?
Antonio Macciò, Sara Oppi & Clelia Madeddu 
Review  |   Published: 08 February 2021


Investigation on factors associated with ovarian cancer: an umbrella review of systematic review and meta-analyses
Kiarash Tanha, Azadeh Mottaghi, Marzieh Nojomi, Marzieh Moradi, Rezvan Rajabzadeh, Samaneh Lotfi & Leila Janani  
Review  |   Published: 11 November 2021


MiR-149-3p promotes the cisplatin resistance and EMT in ovarian cancer through downregulating TIMP2 and CDKN1A
Jin Wang & Lingxia Liu 
Research |   Published: 19 November 2021


RNA-binding protein IGF2BP2 enhances circ_0000745 abundancy and promotes aggressiveness and stemness of ovarian cancer cells via the microRNA-3187-3p/ERBB4/PI3K/AKT axis
Shengtan Wang, Zaihong Li, Genhai Zhu, Lan Hong, Chunyan Hu, Kang Wang, Kaiying Cui & Chunbo Hao
Research |   Published: 13 November 2021


Propofol suppresses cell viability, cell cycle progression and motility and induces cell apoptosis of ovarian cancer cells through suppressing MEK/ERK signaling via targeting circVPS13C/miR-145 axis
Huan Lu, Guanlin Zheng, Xiang Gao, Chanjuan Chen, Min Zhou & Longxin Zhang 
Research |   Published: 09 February 2021


MiR-585-3p suppresses tumor proliferation and migration by directly targeting CAPN9 in high grade serous ovarian cancer
Xiaoyuan Lu, Guilin Li, Sicong Liu, Haihong Wang & Buze Chen 
Research |   Published: 08 July 2021


Establishment and validation of an RNA binding protein-associated prognostic model for ovarian cancer
Chaofan He, Fuxin Huang, Kejia Zhang, Jun Wei, Ke Hu & Meng Liang 
Research |   Published: 07 February 2021


Exosomes secreted by chemoresistant ovarian cancer cells promote angiogenesis
Zhang Li, Wang Yan-qing, Yang Xiao, Liu Shi-yi, Yuan Meng-qin, Xian Shu, Yang Dong-yong, Zheng Ya-jing & Cheng Yan-xiang 
Research |   Published: 07 January 2021


MicroRNAs as the critical regulators of Cisplatin resistance in ovarian cancer cells
Meysam Moghbeli 
Review |   Published: 30 September 2021


Early clearance of serum HE4 and CA125 in predicting platinum sensitivity and prognosis in epithelial ovarian cancer
Yan Rong & Li Li 
Research |   Published: 04 January 2021


Comprehensive analyses of glycolysis-related lncRNAs for ovarian cancer patients
Jianfeng Zheng, Jialu Guo, Linling Zhu, Ying Zhou & Jinyi Tong 
Research |   Published: 24 September 2021


Investigation on factors associated with ovarian cancer: an umbrella review of systematic review and meta-analyses
Kiarash Tanha, Azadeh Mottaghi, Marzieh Nojomi, Marzieh Moradi, Rezvan Rajabzadeh, Samaneh Lotfi & Leila Janani  
Review  |   Published: 11 November 2021
Altmetric Attention


COVID-19 and cytokine storm syndrome: can what we know about interleukin-6 in ovarian cancer be applied?
Antonio Macciò, Sara Oppi & Clelia Madeddu 
Review  |   Published: 08 February 2021
Altmetric Attention


Comorbidities and inflammation associated with ovarian cancer and its influence on SARS-CoV-2 infection
Sima Chaudhari, Satyajit Dey Pereira, Meshach Asare-Warehene, Ritam Naha, Shama Prasada Kabekkodu, Benjamin K. Tsang & Kapaettu Satyamoorthy 
Review  |   Published: 25 February 2021
Altmetric Attention


Comprehensive analyses of glycolysis-related lncRNAs for ovarian cancer patients
Jianfeng Zheng, Jialu Guo, Linling Zhu, Ying Zhou & Jinyi Tong 
Research |   Published: 24 September 2021
Altmetric Attention


Pretreatment with LCK inhibitors chemosensitizes cisplatin‐resistant endometrioid ovarian tumors
Katie K. Crean-Tate, Chad Braley, Goutam Dey, Emily Esakov, Caner Saygin, Alexandria Trestan, Daniel J. Silver, Soumya M. Turaga, Elizabeth V. Connor, Robert DeBernardo, Chad M. Michener, Peter G. Rose, Justin Lathia & Ofer Reizes
Research |   Published: 22 April 2021
Altmetric Attention


Comparison of the survival outcomes of laparoscopy versus laparotomy in treatment of early-stage ovarian cancer: a systematic review and meta-analysis
Qingduo Kong, Hongyi Wei, Jing Zhang, Yilin Li & Yongjun Wang 
Research |   Published: 16 March 2021
Altmetric Attention


Predicting chemoresponsiveness in epithelial ovarian cancer patients using circulating small extracellular vesicle-derived plasma gelsolin
Emma Gerber, Meshach Asare-Werehene, Arkadiy Reunov, Dylan Burger, Tien Le, Euridice Carmona, Anne-Marie Mes-Masson & Benjamin K. Tsang 
Research |   Published: 16 January 2023
Altmetric Attention


A bioinformatics analysis: ZFHX4 is associated with metastasis and poor survival in ovarian cancer
Shuai Zong, Ping-ping Xu, Yin-hai Xu & Yi Guo 
Research |   Published: 01 August 2022
Altmetric Attention


Using genetically encoded fluorescent biosensors to interrogate ovarian cancer metabolism
Shree Bose, Haipei Yao, Qiang Huang, Regina Whitaker, Christopher D. Kontos, Rebecca A. Previs & Xiling Shen 
Research |   Published: 20 October 2022
Altmetric Attention


Submit manuscript

Annual Journal Metrics

  • Citation Impact 2023
    Journal Impact Factor: 3.8
    5-year Journal Impact Factor: 4.2
    Source Normalized Impact per Paper (SNIP): 0.957
    SCImago Journal Rank (SJR): 0.968

    Speed 2023
    Submission to first editorial decision (median days): 7
    Submission to acceptance (median days): 138

    Usage 2023
    Downloads: 1,114,260
    Altmetric mentions: 475

News

A new FDA approved phase I/II clinical trial on recurrent ovarian cancer is now open for enrollment.

Currently recruiting patients at the Brown Cancer Center, University of Louisville, Louisville, KY. UofL. IRB# 22.0392. NCT# 05610735. Please contact: Dr. Whitney Goldsberry or Dr. Sham S. Kakar.

New Content ItemEditor-in-Chief Dr Ben Tsang has been recognised by the Canadian Parliament for significant contributions to science. Please join us in celebrating this amazing achievement.

New Content ItemEditor-in-Chief Dr Sham Kakar has been recognised as being among the top 2% most-cited researchers in the world. Please join us in celebrating this amazing achievement. 

Read more here.

Journal of Ovarian Research

ISSN: 1757-2215

Contact us